6 days Ago By ABMN Staff
Mariner LLC lessened its holdings in Genmab A/S ( NASDAQ:GMAB – Free Report ) by 2.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,700 shares of the company’s stock after selling 1,079 shares during the quarter.
Mariner LLC’s holdings in Genmab A/S were worth $766,000 as of its most recent filing with the Securities and Exchange Commission. Other institutional investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its holdings in Genmab A/S by 295.
3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC boosted its holdings in Genmab A/S by 105.
4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after purchasing an additional 950 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Genmab A/S by 96.
6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares in the last quarter. Barclays PLC boosted its stake in shares of Genmab A/S by 1,072.
8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after acquiring an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC boosted its stake in shares of Genmab A/S by 656.
8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after acquiring an additional 2,496 shares in the last quarter. Hedge funds and other institutional investors own 7.
07% of the company’s stock. Analyst Ratings Changes Several equities research analysts have recently commented on GMAB shares. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th.
Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th.
HC Wainwright reissued a “buy” rating and set a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th.
Finally, Sanford C. Bernstein lowered Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock.
According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.17.
Genmab A/S Stock Performance Shares of GMAB opened at $20.63 on Tuesday. The stock has a fifty day moving average of $20.
45 and a two-hundred day moving average of $21.00. The company has a market capitalization of $13.
66 billion, a PE ratio of 11.86, a price-to-earnings-growth ratio of 2.65 and a beta of 1.
07. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $30.
41. Genmab A/S ( NASDAQ:GMAB – Get Free Report ) last issued its earnings results on Wednesday, February 12th. The company reported $0.
57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29.
Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.
As a group, equities research analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year. About Genmab A/S ( Free Report ) Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Read More Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter .
.
